These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 35859218)

  • 1. Fusobacterium nucleatum load in MSI colorectal cancer subtypes.
    Ono T; Yamaguchi T; Takao M; Kojika E; Iijima T; Horiguchi SI
    Int J Clin Oncol; 2022 Oct; 27(10):1580-1588. PubMed ID: 35859218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusobacterium nucleatum in colorectal carcinoma tissue and patient prognosis.
    Mima K; Nishihara R; Qian ZR; Cao Y; Sukawa Y; Nowak JA; Yang J; Dou R; Masugi Y; Song M; Kostic AD; Giannakis M; Bullman S; Milner DA; Baba H; Giovannucci EL; Garraway LA; Freeman GJ; Dranoff G; Garrett WS; Huttenhower C; Meyerson M; Meyerhardt JA; Chan AT; Fuchs CS; Ogino S
    Gut; 2016 Dec; 65(12):1973-1980. PubMed ID: 26311717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.
    Zlobec I; Kovac M; Erzberger P; Molinari F; Bihl MP; Rufle A; Foerster A; Frattini M; Terracciano L; Heinimann K; Lugli A
    Int J Cancer; 2010 Dec; 127(11):2569-75. PubMed ID: 20162668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR.
    Bettstetter M; Dechant S; Ruemmele P; Grabowski M; Keller G; Holinski-Feder E; Hartmann A; Hofstaedter F; Dietmaier W
    Clin Cancer Res; 2007 Jun; 13(11):3221-8. PubMed ID: 17545526
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Hamada T; Zhang X; Mima K; Bullman S; Sukawa Y; Nowak JA; Kosumi K; Masugi Y; Twombly TS; Cao Y; Song M; Liu L; da Silva A; Shi Y; Gu M; Li W; Koh H; Nosho K; Inamura K; Keum N; Wu K; Meyerhardt JA; Kostic AD; Huttenhower C; Garrett WS; Meyerson M; Giovannucci EL; Chan AT; Fuchs CS; Nishihara R; Giannakis M; Ogino S
    Cancer Immunol Res; 2018 Nov; 6(11):1327-1336. PubMed ID: 30228205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral Fusobacterium nucleatum abundance correlates with macrophage infiltration and CDKN2A methylation in microsatellite-unstable colorectal carcinoma.
    Park HE; Kim JH; Cho NY; Lee HS; Kang GH
    Virchows Arch; 2017 Sep; 471(3):329-336. PubMed ID: 28597080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features of sporadic MSI colorectal cancer and Lynch syndrome: a single-center retrospective cohort study.
    Nakayama Y; Iijima T; Inokuchi T; Kojika E; Takao M; Takao A; Koizumi K; Horiguchi SI; Hishima T; Yamaguchi T
    Int J Clin Oncol; 2021 Oct; 26(10):1881-1889. PubMed ID: 34148153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of the Fusobacterium nucleatum status in colorectal cancers.
    Chen Y; Lu Y; Ke Y; Li Y
    Medicine (Baltimore); 2019 Sep; 98(39):e17221. PubMed ID: 31574832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between
    Proença MA; Biselli JM; Succi M; Severino FE; Berardinelli GN; Caetano A; Reis RM; Hughes DJ; Silva AE
    World J Gastroenterol; 2018 Dec; 24(47):5351-5365. PubMed ID: 30598580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Fusobacterium nucleatum with clinical and molecular features in colorectal serrated pathway.
    Ito M; Kanno S; Nosho K; Sukawa Y; Mitsuhashi K; Kurihara H; Igarashi H; Takahashi T; Tachibana M; Takahashi H; Yoshii S; Takenouchi T; Hasegawa T; Okita K; Hirata K; Maruyama R; Suzuki H; Imai K; Yamamoto H; Shinomura Y
    Int J Cancer; 2015 Sep; 137(6):1258-68. PubMed ID: 25703934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profile and copy number analysis of sporadic colorectal cancer in Taiwan.
    Lin CH; Lin JK; Chang SC; Chang YH; Chang HM; Liu JH; Li LH; Chen YT; Tsai SF; Chen WS
    J Biomed Sci; 2011 Jun; 18(1):36. PubMed ID: 21645411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MSI status is associated with distinct clinicopathological features in BRAF mutation colorectal cancer: A systematic review and meta-analysis.
    Wu M; Kim YS; Ryu HS; Choi SC; Kim KY; Park WC; Kim MS; Myung JY; Choi HS; Kim EJ; Lee MY
    Pathol Res Pract; 2020 Jan; 216(1):152791. PubMed ID: 31866097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer.
    Seppälä TT; Böhm JP; Friman M; Lahtinen L; Väyrynen VM; Liipo TK; Ristimäki AP; Kairaluoma MV; Kellokumpu IH; Kuopio TH; Mecklin JP
    Br J Cancer; 2015 Jun; 112(12):1966-75. PubMed ID: 25973534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer.
    Goel A; Nagasaka T; Arnold CN; Inoue T; Hamilton C; Niedzwiecki D; Compton C; Mayer RJ; Goldberg R; Bertagnolli MM; Boland CR
    Gastroenterology; 2007 Jan; 132(1):127-38. PubMed ID: 17087942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer.
    Loughrey MB; Waring PM; Tan A; Trivett M; Kovalenko S; Beshay V; Young MA; McArthur G; Boussioutas A; Dobrovic A
    Fam Cancer; 2007; 6(3):301-10. PubMed ID: 17453358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum.
    Kambara T; Simms LA; Whitehall VL; Spring KJ; Wynter CV; Walsh MD; Barker MA; Arnold S; McGivern A; Matsubara N; Tanaka N; Higuchi T; Young J; Jass JR; Leggett BA
    Gut; 2004 Aug; 53(8):1137-44. PubMed ID: 15247181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF V600E-specific immunohistochemistry for the exclusion of Lynch syndrome in MSI-H colorectal cancer.
    Capper D; Voigt A; Bozukova G; Ahadova A; Kickingereder P; von Deimling A; von Knebel Doeberitz M; Kloor M
    Int J Cancer; 2013 Oct; 133(7):1624-30. PubMed ID: 23553055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fusobacterium nucleatum Load Correlates with KRAS Mutation and Sessile Serrated Pathogenesis in Colorectal Adenocarcinoma.
    Takeda K; Koi M; Okita Y; Sajibu S; Keku TO; Carethers JM
    Cancer Res Commun; 2023 Sep; 3(9):1940-1951. PubMed ID: 37772997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.